What is Daraxonrasib, the promising cancer drug for pancreatic cancer that is available to some terminally ill patients?

At the beginning of May, the U.S. Food and Drug Administration (FDA) announced that it would allow some pancreatic cancer patients to access a drug that promises to treat the disease earlier than initially planned. This drug is called Daraxonrasib, which is taken in three pills daily, and has not yet been approved for general use by the U.S. agency. However, it has shown promising results in clinical trials. The FDA's decision follows a request from the company developing the drug, Revolution Medicines, to authorize its administration to patients through a specific regulatory process. The company claims that, to date, no one has received Daraxonrasib outside of clinical trials. It remains in an experimental phase. Nevertheless, the FDA determined that patients with metastatic pancreatic cancer who have received prior treatment may be eligible to access the drug. Revolution Medicines announced that it will provide the drug through a program at no cost to selected patients. It is important to note that the FDA's decision is only valid in the United States, and patient requests must be made by a licensed physician in that country, according to the New York Times. Daraxonrasib: The promising drug against pancreatic cancer available to some terminally ill patients. Photo: reference. Daraxonrasib: The promising drug against pancreatic cancer. Daraxonrasib works on a mutated protein called KRAS, which drives the growth of almost all pancreatic cancers, as well as many lung and colon cancers, according to specialists interviewed by the aforementioned media outlet. In mid-April, Revolution Medicines announced that the drug doubled the survival time of patients who participated in a late-stage clinical trial. The company stated that those who received the medication lived for more than 13 months, compared to less than seven months for those who received chemotherapy. The study involved 501 patients with metastatic pancreatic cancer who had already received one line of chemotherapy. Professor Brian M. Wolpin, of Harvard Medical School and the principal investigator of the trial, stated in a company press release: "For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival and improve quality of life." "The results of this widely anticipated study indicate that Daraxonrasib represents a clear and very significant advance for patients with pancreatic cancer who have experienced progression after prior treatment, typically chemotherapy." Wolpin, who is also director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, added: "I believe that this new approach is a very important advance for the field, which I expect will transform the clinical practice of physicians and improve the care of patients with metastatic pancreatic cancer who have been previously treated." Despite the results obtained so far, the medication often causes side effects such as rash, diarrhea, fatigue, and nausea, according to information compiled by the Times. In an interview with the aforementioned newspaper, former Republican Senator Ben Sasse of Nebraska, who has pancreatic cancer and participated in clinical trials of the drug, said that its use caused a rash on his face. However, he said, it reduced his fears and allowed him to decrease his dose of pain medication. The announcement made by the FDA this month comes amid a situation where patients and their families have urged the government agency to approve broader access to the drug. One of their main arguments is that their health conditions do not allow them enough time to wait for regulatory approval. The administration of President Donald Trump has designated the drug for expedited review. It is presumed that it could potentially be approved by the end of 2026.